Recurrent SARS-CoV-2 spike mutations confer growth advantages to select JN.1 sublineages

Wang Q, Mellis IA, Ho J, Bowen A, Kowalski-Dobson T, Valdez R, Katsamba PS, Wu M, Lee C, Shapiro L, Gordon A, Guo Y, Ho DD, Liu L. (2024). Emerg Microbes Infect. 2024 Dec;13(1):2402880. 

10.1080/22221751.2024.2402880.

SARS-CoV-2 omicron BA.2.87.1 exhibits higher susceptibility to serum neutralization than EG.5.1 and JN.1

Wang Q, Guo Y, Schwanz LT, Mellis IA, Sun Y, Qu Y, Urtecho G, Valdez R, Stoneman E, Gordon A, Wang HH, Ho DD, Liu. (2024). Emerg Microbes Infect. 2024 Dec;13(1):2359004.

10.1080/22221751.2024.2359004

XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1

Wang Q, Guo Y, Bowen A, Mellis IA, Valdez R, Gherasim C, Gordon A, Liu L, Ho DD. (2024). Cell Host Microbe. 2024 Feb 10:S1931-3128(24)00018-0.

10.1016/j.chom.2024.01.014

Reduction in Long COVID Symptoms and Symptom Severity in Vaccinated Compared to Unvaccinated Adults

Maier HE, Kowalski-Dobson T, Eckard A, Gherasim C, Manthei D, Meyers A, Davis D, Bakker K, Lindsey K, Chu Z, Warsinske L, Arnold M, Buswinka A, Stoneman E, Valdez R, Gordon A. (2024). Open Forum Infect Dis. 2024 Jan 23;11(2):ofae039.

10.1093/ofid/ofae039

Evolving antibody evasion and receptor affinity of the Omicron BA.2.75 sublineage of SARS-CoV-2

Qian Wang, Zhiteng Li, Yicheng Guo, Ian A. Mellis, Sho Iketani, Michael Liu, Jian Yu, Riccardo Valdez, Adam S. Lauring, Zizhang Sheng, Aubree Gordon, Lihong Liu, David D. Ho. (2023). iScience. 2023 Oct 18;26(11):108254. 10.1016/j.isci.2023.108254.

SARS-CoV-2 neutralising antibodies after a second BA.5 bivalent booster

Wang Q, Bowen A, Ho J, Zhang RM, Valdez R, Stoneman E, Gordon A, Liu L, Ho DD. (2023). The Lancet, Oct 31:S0140-6736(23)

10.1016/S0140-6736(23)02278-X

Deep immunological imprinting due to the ancestral spike in the current bivalent COVID-19 vaccine.

Wang Q, Guo Y, Tam AR, Valdez R, Gordon A, Liu L, Ho DD. (2023). Cell Rep Med, Oct 24:101258

10.1016/j.xcrm.2023.101258

Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike 

Wang Q, Guo Y, Liu L, Schwanz LT, Li Z, Nair MS, Ho J, Zhang RM, Iketani S, Yu J, Huang Y, Qu Y, Valdez R, Lauring AS, Huang Y, Gordon A, Wang HH, Liu L, Ho DD (2023). Nature, 23

https://doi.org/10.1038/s41586-023-06750-w

Antibody neutralization of emerging SARS-CoV-2 subvariants: EG.5.1 and XBC.1.6 Wang Q, Guo Y, Zhang RM, Ho J, Mohri H, Valdez R, Manthei DM, Gordon A, Liu L, Ho DD (2023). Lancet Infect Diseases, 23(10), e397-e398. https://www.sciencedirect.com/science/article/pii/S1473309923005558?via%3Dihub

SARS-CoV-2 neutralizing antibodies after bivalent versus monovalent booster
Wang Q, Bowen A, Tam AR, Valdez R, Stoneman E, Mellis IA, Gordon A, Liu L, Ho DD. (2023). Lancet Infect Diseases, 23(5), 527-528. https://www.sciencedirect.com/science/article/pii/S1473309923001810?via%3Dihub

Antibody Response to Omicron BA.4-BA.5 Bivalent Booster
Wang, Q., Bowen, A., Valdez, R., Gherasim, C., Gordon, A., Liu, L., & Ho, D. D. (2023). The New England Journal of Medicine, 388(6), 567–569. https://doi.org/10.1056/NEJMc2213907

Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants
Wang, Q., Iketani, S., Li, Z., Liu, L., Guo, Y., Huang, Y., Bowen, A. D., Liu, M., Wang, M., Yu, J., Valdez, R., Lauring, A. S., Sheng, Z., Wang, H. H., Gordon, A., Liu, L., & Ho, D. D. (2023). Cell, 186(2), 279–286.e8. https://doi.org/10.1016/j.cell.2022.12.018

PARIS and SPARTA: Finding the Achilles’ heel of SARS-CoV-2

Simon, V, Kota, V, Bloomquist, RF, Hanley, HB,  Forgacs, D, Pahwa, S, Pallikkuth, S, Miller, LG, Schaenman, J, Yeaman, MR, Manthei, D, Wolf, J, Gaur, AH,  Estepp, JH, Srivastava, K, Carreño, JM, Cuevas, F, PARIS/SPARTA study group, Ellebedy, AH, Gordon, A, Valdez, R, Cobey, S, Reed, EF, Kolhe, R, Thomas, PG, Schultz-Cherry, S, Ross, TM, Krammer, F. (2022). mSphere. https://digitalcommons.wustl.edu/open_access_pubs/12061/ 

Characterization of the emerging SARS-CoV-2 B.1.621 (Mu) variant

Halfmann, PJ,  Kuroda, M,  Armbrust, T, Theiler, J, Balaram, A, Moreno, GK, Accola, MA, Valdez, R, Kowalski-Dobson, T, Braun, K, Yamayoshi, S, Somsen, E, Baczenas, JJ, McLaughlin, M, Rehrauer, W, Imai, M, Friedrich, TC, O’Connor, SL, O’Conner, D, Gordon, A, Korber, B, and Kawaoka, Y.  (2022). ScienceTranslational Medicine. https://www.science.org/doi/10.1126/scitranslmed.abm4908 

Defining the risk of SARS-CoV-2 variants on immune protection
DeGrace, M.M., Ghedin, E., Frieman, M.B. et al. (2022). Nature. https://doi.org/10.1038/s41586-022-04690-5 

Characterization of a new SARS-CoV-2 variant that emerged in Brazil
Imai M, Halfmann PJ, Yamayoshi S, Iwatsuki-Horimoto K, Chiba S, Watanabe T, Nakajima N, Ito M, Kuroda M, Kiso M, Maemura T, Takahashi K, Loeber S, Hatta M, Koga M, Nagai H, Yamamoto S, Saito M, Adachi E, Akasaka O, Nakamura M, Nakachi I, Ogura T, Baba R, Fujita K, Ochi J, Mitamura K, Kato H, Nakajima H, Yagi K, Hattori SI, Maeda K, Suzuki T, Miyazato Y, Valdez R, Gherasim C, Furusawa Y, Okuda M, Ujie M, Lopes TJS, Yasuhara A, Ueki H, Sakai-Tagawa Y, Eisfeld AJ, Baczenas JJ, Baker DA, O'Connor SL, O'Connor DH, Fukushi S, Fujimoto T, Kuroda Y, Gordon A, Maeda K, Ohmagari N, Sugaya N, Yotsuyanagi H, Mitsuya H, Suzuki T, Kawaoka Y. (2022) Proceedings of the National Academy of Sciences (PNAS) USA. https://www.pnas.org/doi/10.1073/pnas.2106535118 

Long-Term, Infection-Acquired Immunity Against the SARS-CoV-2 Delta Variant in a Hamster Model
Halfmann, P, Kuroda, M, Armbrust, T, Accola, M, Valdez, R, Kowalski-Dobson, T, Rehrauer, W, Gordon, A, Kawaoka, Y. (2022). Cell Reports. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801307/